L3VLUP
ProSign in

COGT · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

COGTJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • COGT
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterCOGTJNJ
Q3 2020none listed holders, n.a.30 holders, $26.2bn
Q4 20202 holders, $8.0m32 holders, $26.6bn
Q1 20212 holders, $6.4m31 holders, $25.3bn
Q2 20212 holders, $17m37 holders, $25.6bn
Q3 20211 holders, $5.0m40 holders, $24.1bn
Q4 20211 holders, $5.1m33 holders, $25.2bn
Q1 20221 holders, $6.4m35 holders, $28.2bn
Q2 20221 holders, $9.0m33 holders, $26.9bn
Q3 20221 holders, $3.7m36 holders, $25.4bn
Q4 20223 holders, $11m35 holders, $27.6bn
Q1 20234 holders, $63m42 holders, $24.5bn
Q2 20233 holders, $93m38 holders, $25.0bn
Q3 20234 holders, $59m37 holders, $18.9bn
Q4 20233 holders, $35m31 holders, $19.0bn
Q1 20243 holders, $53m32 holders, $19.7bn
Q2 20244 holders, $97m35 holders, $20.4bn
Q3 20244 holders, $120m28 holders, $22.3bn
Q4 20244 holders, $47m37 holders, $20.4bn
Q1 20253 holders, $42m32 holders, $20.5bn
Q2 20253 holders, $43m31 holders, $18.4bn
Q3 20254 holders, $92m32 holders, $23.7bn
Q4 20259 holders, $1.3bn29 holders, $27.8bn
Q1 202611 holders, $1.6bn34 holders, $35.6bn
Q2 20267 holders, $1.6bn33 holders, $39.1bn
COGT

Cogent Biosciences Inc

Holders
9
Reported value
$1.3bn
Buyers
24
Sellers
5

Breadth +19 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
29
Reported value
$27.8bn
Buyers
13
Sellers
26

Breadth -13 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2025

Among the 33 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only COGT (4)

Balyasny Asset Management LLC, Farallon Capital Management LLC, Holocene Advisors LP, Voloridge Investment Management LLC

Only JNJ (24)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Dodge & Cox, Element Capital Management LLC, Freestone Grove Partners LP, GAMCO Investors Inc, Hudson Bay Capital Management LP, Invesco Ltd, Man Group PLC, Markel Group Inc, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Rokos Capital Management LLP, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Wellington Management Group LLP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →